Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Snake venom secretory phospholipase A2 (svPLA2) enzymes are critical, highly toxic components found in the venoms of almost all medically important snake families, including Viperidae and Elapidae. These small, calcium-dependent enzymes catalyze the hydrolysis of the sn-2 ester bond of membrane glycerophospholipids, releasing free fatty acids (such as arachidonic acid) and lysophospholipids. This enzymatic activity, along with non-enzymatic interactions, leads to severe pathological effects including myonecrosis, neurotoxicity, paralysis, acute kidney injury, and systemic inflammatory responses. Consequently, svPLA2 is a primary therapeutic target for treating snakebite envenomation, which is classified as a high-priority neglected tropical disease. Small-molecule inhibitors, most notably varespladib and its orally bioavailable prodrug varespladib-methyl, act as potent competitive inhibitors of svPLA2, effectively neutralizing its toxicity and offering a promising adjunct or alternative to traditional antibody-based antivenoms.
Inhibition of snake venom secretory phospholipase A2 (svPLA2) enzymatic activity, preventing the hydrolysis of cell membrane phospholipids and subsequent release of inflammatory fatty acids and lysophospholipids, thereby mitigating tissue damage, neurotoxicity, and systemic inflammation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snake venom secretory phospholipase A2 (svPLA2).